{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:06:45Z","timestamp":1793210805531,"version":"4.5.0"},"reference-count":113,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intravenous immunoglobulin (IVIG) is a pooled preparation of normal IgG obtained from several thousand healthy donors. It is widely used in the immunotherapy of a large number of autoimmune and inflammatory diseases. The mechanisms of action of IVIG are complex and, as discussed in this review, experimental and clinical data provide an indicator that the therapeutic benefit of IVIG therapy is due to several mutually non-exclusive mechanisms affecting soluble mediators as well as cellular components of the immune system. These mechanisms depend on Fc and\/or F(ab\u2032)2 fragments. A better understanding of the effector functions of IVIG should help in identification of biomarkers of responses to IVIG in autoimmune patients.<\/jats:p>","DOI":"10.1093\/intimm\/dxx039","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T11:10:25Z","timestamp":1498561825000},"page":"491-498","source":"Crossref","is-referenced-by-count":250,"title":["IVIG-mediated effector functions in autoimmune and inflammatory diseases"],"prefix":"10.1093","volume":"29","author":[{"given":"Caroline","family":"Galeotti","sequence":"first","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit\u00e9, France"},{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, Paris, France"},{"name":"Centre de Recherche des Cordeliers, Equipe -Immunopathologie et Immunointervention Th\u00e9rapeutique, Paris, France"},{"name":"Department of Pediatric Rheumatology, National Referral Centre of Auto-inflammatory Diseases, CHU de Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srini V","family":"Kaveri","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit\u00e9, France"},{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, Paris, France"},{"name":"Centre de Recherche des Cordeliers, Equipe -Immunopathologie et Immunointervention Th\u00e9rapeutique, Paris, France"},{"name":"Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagadeesh","family":"Bayry","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale Unit\u00e9, France"},{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, Paris, France"},{"name":"Centre de Recherche des Cordeliers, Equipe -Immunopathologie et Immunointervention Th\u00e9rapeutique, Paris, France"},{"name":"Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,20]]},"reference":[{"key":"2022082522372331700_CIT0001","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc\u03b3 receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat. Rev. Immunol"},{"key":"2022082522372331700_CIT0002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol. Rev"},{"key":"2022082522372331700_CIT0003","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N. Engl. J. Med"},{"key":"2022082522372331700_CIT0004","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrrheum.2011.61","article-title":"Intravenous immunoglobulin therapy in rheumatic diseases","volume":"7","author":"Bayry","year":"2011","journal-title":"Nat. Rev. Rheumatol"},{"key":"2022082522372331700_CIT0005","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"2022082522372331700_CIT0006","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology\u2013mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat. Rev. Neurol"},{"key":"2022082522372331700_CIT0007","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1503\/cmaj.130375","article-title":"Intravenous immunoglobulin as clinical immune-modulating therapy","volume":"187","author":"Gilardin","year":"2015","journal-title":"CMAJ"},{"key":"2022082522372331700_CIT0008","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(84)90701-3","article-title":"Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin","volume":"2","author":"Sultan","year":"1984","journal-title":"Lancet"},{"key":"2022082522372331700_CIT0009","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaut.2006.11.002","article-title":"Idiotypic and anti-idiotypic elastin autoantibodies: implications for IVIg and pregnancy loss","volume":"28","author":"Konova","year":"2007","journal-title":"J. Autoimmun"},{"key":"2022082522372331700_CIT0010","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/intimm\/dxm052","article-title":"The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model","volume":"19","author":"Blank","year":"2007","journal-title":"Int. Immunol"},{"key":"2022082522372331700_CIT0011","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J. Clin. Invest"},{"key":"2022082522372331700_CIT0012","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2003-05-1530","article-title":"Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level","volume":"103","author":"Lutz","year":"2004","journal-title":"Blood"},{"key":"2022082522372331700_CIT0013","doi-asserted-by":"crossref","first-page":"14104","DOI":"10.1073\/pnas.0700506104","article-title":"Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death","volume":"104","author":"Arumugam","year":"2007","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2022082522372331700_CIT0014","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nm836","article-title":"F(ab)\u20192-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins","volume":"9","author":"Basta","year":"2003","journal-title":"Nat. Med"},{"key":"2022082522372331700_CIT0015","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM198605083141907","article-title":"Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody","volume":"314","author":"Clarkson","year":"1986","journal-title":"N. Engl. J. Med"},{"key":"2022082522372331700_CIT0016","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0140-6736(93)92000-J","article-title":"Infusion of Fc\u03b3 fragments for treatment of children with acute immune thrombocytopenic purpura","volume":"342","author":"Debr\u00e9","year":"1993","journal-title":"Lancet"},{"key":"2022082522372331700_CIT0017","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor","volume":"93","author":"Junghans","year":"1996","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2022082522372331700_CIT0018","first-page":"1328","article-title":"The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease","volume":"113","author":"Akilesh","year":"2004","journal-title":"J. Clin. Invest"},{"key":"2022082522372331700_CIT0019","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J. Clin. Invest"},{"key":"2022082522372331700_CIT0020","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1182\/blood-2010-05-284919","article-title":"Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy","volume":"116","author":"Chen","year":"2010","journal-title":"Blood"},{"key":"2022082522372331700_CIT0021","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1182\/blood-2011-08-374223","article-title":"The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia","volume":"118","author":"Crow","year":"2011","journal-title":"Blood"},{"key":"2022082522372331700_CIT0022","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.celrep.2015.09.013","article-title":"Pathways responsible for human autoantibody and therapeutic intravenous IgG activity in humanized mice","volume":"13","author":"Schwab","year":"2015","journal-title":"Cell Rep"},{"key":"2022082522372331700_CIT0023","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"key":"2022082522372331700_CIT0024","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1074-7613(03)00080-3","article-title":"Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease","volume":"18","author":"Bruhns","year":"2003","journal-title":"Immunity"},{"key":"2022082522372331700_CIT0025","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"2022082522372331700_CIT0026","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1154315","article-title":"Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc","volume":"320","author":"Anthony","year":"2008","journal-title":"Science"},{"key":"2022082522372331700_CIT0027","doi-asserted-by":"crossref","first-page":"E1297","DOI":"10.1073\/pnas.1422481112","article-title":"Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity","volume":"112","author":"Washburn","year":"2015","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2022082522372331700_CIT0028","doi-asserted-by":"crossref","first-page":"19571","DOI":"10.1073\/pnas.0810163105","article-title":"Identification of a receptor required for the anti-inflammatory activity of IVIG","volume":"105","author":"Anthony","year":"2008","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2022082522372331700_CIT0029","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature10134","article-title":"Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway","volume":"475","author":"Anthony","year":"2011","journal-title":"Nature"},{"key":"2022082522372331700_CIT0030","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/eji.201344230","article-title":"Broad requirement for terminal sialic acid residues and Fc\u03b3RIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo","volume":"44","author":"Schwab","year":"2014","journal-title":"Eur. J. Immunol"},{"key":"2022082522372331700_CIT0031","doi-asserted-by":"crossref","first-page":"E2385","DOI":"10.1073\/pnas.1505292112","article-title":"Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs","volume":"112","author":"Fiebiger","year":"2015","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2022082522372331700_CIT0032","doi-asserted-by":"crossref","first-page":"e107772","DOI":"10.1371\/journal.pone.0107772","article-title":"Different IVIG glycoforms affect in vitro inhibition of anti-ganglioside antibody-mediated complement deposition","volume":"9","author":"Sudo","year":"2014","journal-title":"PLoS ONE"},{"key":"2022082522372331700_CIT0033","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri3401-c1","article-title":"IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist","volume":"14","author":"von Gunten","year":"2014","journal-title":"Nat. Rev. Immunol"},{"key":"2022082522372331700_CIT0034","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1038\/srep05672","article-title":"Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients","volume":"4","author":"Sharma","year":"2014","journal-title":"Sci. Rep"},{"key":"2022082522372331700_CIT0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12974-017-0818-5","article-title":"Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy","volume":"14","author":"Maddur","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"2022082522372331700_CIT0036","doi-asserted-by":"crossref","first-page":"e81448","DOI":"10.1371\/journal.pone.0081448","article-title":"Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G","volume":"8","author":"Ogata","year":"2013","journal-title":"PLoS ONE"},{"key":"2022082522372331700_CIT0037","doi-asserted-by":"crossref","first-page":"193ra89","DOI":"10.1126\/scitranslmed.3006277","article-title":"Plasmacytoid dendritic cells, interferon signaling, and Fc\u03b3R contribute to pathogenesis and therapeutic response in childhood immune thrombocytopenia","volume":"5","author":"Sehgal","year":"2013","journal-title":"Sci. Transl. Med"},{"key":"2022082522372331700_CIT0038","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1073\/pnas.0900016106","article-title":"DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells","volume":"106","author":"Bayry","year":"2009","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2022082522372331700_CIT0039","doi-asserted-by":"crossref","first-page":"e37243","DOI":"10.1371\/journal.pone.0037243","article-title":"Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation","volume":"7","author":"K\u00e4sermann","year":"2012","journal-title":"PLoS ONE"},{"key":"2022082522372331700_CIT0040","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1182\/blood-2014-05-576835","article-title":"Inhibition of Fc\u03b3R-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and Fc\u03b3RIIb in human macrophages","volume":"124","author":"Nagelkerke","year":"2014","journal-title":"Blood"},{"key":"2022082522372331700_CIT0041","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cei.12935","article-title":"Fc\u03b3 receptor expression on splenic macrophages in adult immune thrombocytopenia","volume":"188","author":"Audia","year":"2017","journal-title":"Clin. Exp. Immunol"},{"key":"2022082522372331700_CIT0042","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jmb.2013.02.006","article-title":"Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain","volume":"425","author":"Yu","year":"2013","journal-title":"J. Mol. Biol"},{"key":"2022082522372331700_CIT0043","doi-asserted-by":"crossref","first-page":"e21246","DOI":"10.1371\/journal.pone.0021246","article-title":"Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia","volume":"6","author":"Guhr","year":"2011","journal-title":"PLoS ONE"},{"key":"2022082522372331700_CIT0044","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.4049\/jimmunol.1301611","article-title":"Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils","volume":"192","author":"Campbell","year":"2014","journal-title":"J. Immunol"},{"key":"2022082522372331700_CIT0045","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/eji.201444440","article-title":"Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin","volume":"44","author":"Othy","year":"2014","journal-title":"Eur. J. Immunol"},{"key":"2022082522372331700_CIT0046","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1537-2995.2011.03517.x","article-title":"Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin","volume":"52","author":"Leontyev","year":"2012","journal-title":"Transfusion"},{"key":"2022082522372331700_CIT0047","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.1182\/blood-2012-03-415695","article-title":"Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fc\u03b3 receptor for the amelioration of experimental ITP","volume":"119","author":"Leontyev","year":"2012","journal-title":"Blood"},{"key":"2022082522372331700_CIT0048","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1182\/blood-2011-08-376046","article-title":"IgG1 and IVIg induce inhibitory ITAM signaling through Fc\u03b3RIII controlling inflammatory responses","volume":"119","author":"Aloulou","year":"2012","journal-title":"Blood"},{"key":"2022082522372331700_CIT0049","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1007\/s10875-014-0019-2","article-title":"Natural autoantibodies to Fc\u03b3 receptors in intravenous immunoglobulins","volume":"34","author":"Bouhlal","year":"2014","journal-title":"J. Clin. Immunol"},{"key":"2022082522372331700_CIT0050","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/eji.1830250521","article-title":"Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin)","volume":"25","author":"Ruiz de Souza","year":"1995","journal-title":"Eur. J. Immunol"},{"key":"2022082522372331700_CIT0051","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.immuni.2006.11.010","article-title":"FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin","volume":"26","author":"Park-Min","year":"2007","journal-title":"Immunity"},{"key":"2022082522372331700_CIT0052","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1189\/jlb.3VMA0315-078R","article-title":"Intravenous immunoglobulin skews macrophages to an anti-inflammatory, IL-10-producing activation state","volume":"98","author":"Kozicky","year":"2015","journal-title":"J. Leukoc. Biol"},{"key":"2022082522372331700_CIT0053","doi-asserted-by":"crossref","first-page":"19592","DOI":"10.1038\/srep19592","article-title":"Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin","volume":"6","author":"Galeotti","year":"2016","journal-title":"Sci. Rep"},{"key":"2022082522372331700_CIT0054","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00210-012-0765-8","article-title":"Intravenous immunoglobulin preparation attenuates LPS-induced production of pro-inflammatory cytokines in human monocytic cells by modulating TLR4-mediated signaling pathways","volume":"385","author":"Murakami","year":"2012","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol"},{"key":"2022082522372331700_CIT0055","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0735-1097(01)01335-3","article-title":"Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure\u2013modulatory effect of intravenous immunoglobulin","volume":"38","author":"Dam\u00e5s","year":"2001","journal-title":"J. Am. Coll. Cardiol"},{"key":"2022082522372331700_CIT0056","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.4049\/jimmunol.174.9.5837","article-title":"Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease","volume":"174","author":"Abe","year":"2005","journal-title":"J. Immunol"},{"issue":"Pt 8","key":"2022082522372331700_CIT0057","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awh518","article-title":"Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes","volume":"128","author":"Raju","year":"2005","journal-title":"Brain"},{"key":"2022082522372331700_CIT0058","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.molimm.2005.06.024","article-title":"Gene expression profiling of the effects of intravenous immunoglobulin in human whole blood","volume":"43","author":"Ghielmetti","year":"2006","journal-title":"Mol. Immunol"},{"key":"2022082522372331700_CIT0059","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1172\/JCI116862","article-title":"Binding of cytokines to pharmaceutically prepared human immunoglobulin","volume":"92","author":"Svenson","year":"1993","journal-title":"J. Clin. Invest"},{"key":"2022082522372331700_CIT0060","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","article-title":"Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin","volume":"101","author":"Bayry","year":"2003","journal-title":"Blood"},{"key":"2022082522372331700_CIT0061","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1002\/art.11346","article-title":"Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus","volume":"48","author":"Bayry","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2022082522372331700_CIT0062","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2249.2007.03496.x","article-title":"Modulation of dendritic cell development by immunoglobulin G in control subjects and multiple sclerosis patients","volume":"150","author":"Ohkuma","year":"2007","journal-title":"Clin. Exp. Immunol"},{"key":"2022082522372331700_CIT0063","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1182\/blood-2009-06-225417","article-title":"Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation","volume":"115","author":"Aubin","year":"2010","journal-title":"Blood"},{"key":"2022082522372331700_CIT0064","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1182\/blood-2007-07-099549","article-title":"IgG regulates the CD1 expression profile and lipid antigen-presenting function in human dendritic cells via FcgammaRIIa","volume":"111","author":"Smed-S\u00f6rensen","year":"2008","journal-title":"Blood"},{"key":"2022082522372331700_CIT0065","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaut.2012.05.013","article-title":"Effect of IVIg on human dendritic cell-mediated antigen uptake and presentation: role of lipid accumulation","volume":"39","author":"Othy","year":"2012","journal-title":"J. Autoimmun"},{"key":"2022082522372331700_CIT0066","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.4049\/jimmunol.1301260","article-title":"Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production","volume":"192","author":"Tjon","year":"2014","journal-title":"J. Immunol"},{"key":"2022082522372331700_CIT0067","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1002\/art.38082","article-title":"Contrasting mechanisms of interferon-\u03b1 inhibition by intravenous immunoglobulin after induction by immune complexes versus Toll-like receptor agonists","volume":"65","author":"Wiedeman","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2022082522372331700_CIT0068","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nm1416","article-title":"Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells","volume":"12","author":"Siragam","year":"2006","journal-title":"Nat. Med"},{"key":"2022082522372331700_CIT0069","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1182\/blood-2006-05-021568","article-title":"Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations","volume":"108","author":"von Gunten","year":"2006","journal-title":"Blood"},{"key":"2022082522372331700_CIT0070","doi-asserted-by":"crossref","first-page":"e26469","DOI":"10.1371\/journal.pone.0026469","article-title":"A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms","volume":"6","author":"Casulli","year":"2011","journal-title":"PLoS ONE"},{"key":"2022082522372331700_CIT0071","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00431-008-0872-1","article-title":"Increased nitric oxide production by neutrophils in early stage of Kawasaki disease","volume":"168","author":"Yoshimura","year":"2009","journal-title":"Eur. J. Pediatr"},{"key":"2022082522372331700_CIT0072","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2007-04-084061","article-title":"Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion","volume":"111","author":"Chang","year":"2008","journal-title":"Blood"},{"key":"2022082522372331700_CIT0073","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1161\/CIRCRESAHA.112.266411","article-title":"Intravenous immunoglobulins modulate neutrophil activation and vascular injury through Fc\u03b3RIII and SHP-1","volume":"110","author":"Jang","year":"2012","journal-title":"Circ. Res"},{"key":"2022082522372331700_CIT0074","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jaci.2007.01.023","article-title":"Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies","volume":"119","author":"von Gunten","year":"2007","journal-title":"J. Allergy Clin. Immunol"},{"key":"2022082522372331700_CIT0075","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0897.1996.tb00496.x","article-title":"Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with recurrent spontaneous abortion","volume":"35","author":"Ruiz","year":"1996","journal-title":"Am. J. Reprod. Immunol"},{"key":"2022082522372331700_CIT0076","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1600-0897.2005.00356.x","article-title":"High levels of peripheral blood NK cells in women suffering from recurrent spontaneous abortion are reverted from high-dose intravenous immunoglobulins","volume":"55","author":"Perricone","year":"2006","journal-title":"Am. J. Reprod. Immunol"},{"key":"2022082522372331700_CIT0077","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0022-3476(05)80900-X","article-title":"Effect of high doses of intravenously administered immune globulin on natural killer cell activity in peripheral blood","volume":"120","author":"Finberg","year":"1992","journal-title":"J. Pediatr"},{"key":"2022082522372331700_CIT0078","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2007-03-077057","article-title":"Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells","volume":"110","author":"Tha-In","year":"2007","journal-title":"Blood"},{"key":"2022082522372331700_CIT0079","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.4049\/jimmunol.161.7.3781","article-title":"Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway","volume":"161","author":"Prasad","year":"1998","journal-title":"J. Immunol"},{"key":"2022082522372331700_CIT0080","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"179","author":"Kessel","year":"2007","journal-title":"J. Immunol"},{"key":"2022082522372331700_CIT0081","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2007-03-079947","article-title":"Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis","volume":"111","author":"Ephrem","year":"2008","journal-title":"Blood"},{"key":"2022082522372331700_CIT0082","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.jaci.2012.02.050","article-title":"Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3-positive regulatory T cells","volume":"129","author":"Massoud","year":"2012","journal-title":"J. Allergy Clin. Immunol"},{"key":"2022082522372331700_CIT0083","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood-2012-02-413526","article-title":"Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia","volume":"120","author":"Aslam","year":"2012","journal-title":"Blood"},{"key":"2022082522372331700_CIT0084","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3899\/jrheum.111123","article-title":"Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease","volume":"39","author":"Bayry","year":"2012","journal-title":"J. Rheumatol"},{"key":"2022082522372331700_CIT0085","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood-2012-11-468264","article-title":"Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells","volume":"122","author":"Trinath","year":"2013","journal-title":"Blood"},{"key":"2022082522372331700_CIT0086","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/cmi.2014.117","article-title":"Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation","volume":"12","author":"Maddur","year":"2015","journal-title":"Cell. Mol. Immunol"},{"key":"2022082522372331700_CIT0087","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jaci.2013.09.029","article-title":"Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells","volume":"133","author":"Massoud","year":"2014","journal-title":"J. Allergy Clin. Immunol"},{"key":"2022082522372331700_CIT0088","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2008-02-138073","article-title":"Activation of natural regulatory T cells by IgG Fc-derived peptide \u201cTregitopes\u201d","volume":"112","author":"De Groot","year":"2008","journal-title":"Blood"},{"key":"2022082522372331700_CIT0089","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaci.2010.12.1102","article-title":"Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin","volume":"127","author":"Maddur","year":"2011","journal-title":"J. Allergy Clin. Immunol"},{"key":"2022082522372331700_CIT0090","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.autrev.2011.02.007","article-title":"Comparison of different IVIg preparations on IL-17 production by human Th17 cells","volume":"10","author":"Maddur","year":"2011","journal-title":"Autoimmun. Rev"},{"key":"2022082522372331700_CIT0091","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1007\/s10875-012-9752-6","article-title":"Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations","volume":"33","author":"Maddur","year":"2013","journal-title":"J. Clin. Immunol"},{"key":"2022082522372331700_CIT0092","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12026-014-8580-6","article-title":"Intravenous immunoglobulin exerts reciprocal regulation of Th1\/Th17 cells and regulatory T cells in Guillain-Barr\u00e9 syndrome patients","volume":"60","author":"Maddur","year":"2014","journal-title":"Immunol. Res"},{"key":"2022082522372331700_CIT0093","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fimmu.2017.00275","article-title":"Monomeric immunoglobulin A from plasma inhibits human Th17 responses in vitro independent of Fc\u03b1RI and DC-SIGN","volume":"8","author":"Saha","year":"2017","journal-title":"Front. Immunol"},{"key":"2022082522372331700_CIT0094","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/all.12558","article-title":"Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease","volume":"70","author":"Guo","year":"2015","journal-title":"Allergy"},{"key":"2022082522372331700_CIT0095","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.4049\/jimmunol.1201965","article-title":"Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis","volume":"190","author":"Othy","year":"2013","journal-title":"J. Immunol"},{"key":"2022082522372331700_CIT0096","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/art.38627","article-title":"Intravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of Th17 and Treg cells in an interleukin-10-dependent manner","volume":"66","author":"Lee","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2022082522372331700_CIT0097","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1067\/mai.2002.127284","article-title":"Suppression of IL-4- and CD40-induced B-lymphocyte activation by intravenous immunoglobulin is not mediated through the inhibitory IgG receptor FcgammaRIIb","volume":"110","author":"Zhuang","year":"2002","journal-title":"J. Allergy Clin. Immunol"},{"key":"2022082522372331700_CIT0098","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood-2009-12-261461","article-title":"IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes","volume":"116","author":"S\u00e9\u00eft\u00e9","year":"2010","journal-title":"Blood"},{"key":"2022082522372331700_CIT0099","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaut.2011.05.014","article-title":"TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase","volume":"37","author":"S\u00e9it\u00e9","year":"2011","journal-title":"J. Autoimmun"},{"key":"2022082522372331700_CIT0100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.trim.2010.06.012","article-title":"In vitro effects of everolimus and intravenous immunoglobulin on cell proliferation and apoptosis induction in the mixed lymphocyte reaction","volume":"23","author":"Amet","year":"2010","journal-title":"Transpl. Immunol"},{"key":"2022082522372331700_CIT0101","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.clim.2010.01.001","article-title":"Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg)","volume":"135","author":"Paquin Proulx","year":"2010","journal-title":"Clin. Immunol"},{"key":"2022082522372331700_CIT0102","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s10875-010-9469-3","article-title":"IVIg attenuates TLR-9 activation in B cells from SLE patients","volume":"31","author":"Kessel","year":"2011","journal-title":"J. Clin. Immunol"},{"key":"2022082522372331700_CIT0103","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaci.2013.08.042","article-title":"Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells","volume":"133","author":"S\u00e9\u00eft\u00e9","year":"2014","journal-title":"J. Allergy Clin. Immunol"},{"key":"2022082522372331700_CIT0104","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.autrev.2011.08.004","article-title":"B cells are resistant to immunomodulation by \u2018IVIg-educated\u2019 dendritic cells","volume":"11","author":"Maddur","year":"2011","journal-title":"Autoimmun. Rev"},{"key":"2022082522372331700_CIT0105","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/0091-6749(91)90420-S","article-title":"An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma","volume":"87","author":"Mazer","year":"1991","journal-title":"J. Allergy Clin. Immunol"},{"key":"2022082522372331700_CIT0106","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1067\/mai.2001.116291","article-title":"Inhibition of IgE production in vitro by intact and fragmented intravenous immunoglobulin","volume":"108","author":"Zhuang","year":"2001","journal-title":"J. Allergy Clin. Immunol"},{"key":"2022082522372331700_CIT0107","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2002-06-1684","article-title":"Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG","volume":"101","author":"de Grandmont","year":"2003","journal-title":"Blood"},{"key":"2022082522372331700_CIT0108","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10875-007-9082-2","article-title":"BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer","volume":"27","author":"Le Pottier","year":"2007","journal-title":"J. Clin. Immunol"},{"key":"2022082522372331700_CIT0109","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jneuroim.2014.06.007","article-title":"IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"274","author":"Ritter","year":"2014","journal-title":"J. Neuroimmunol"},{"key":"2022082522372331700_CIT0110","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.drudis.2016.08.004","article-title":"Predisposing factors, pathogenesis and therapeutic intervention of Kawasaki disease","volume":"21","author":"Galeotti","year":"2016","journal-title":"Drug Discov. Today"},{"key":"2022082522372331700_CIT0111","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0002-9440(10)65670-2","article-title":"Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases","volume":"153","author":"Xu","year":"1998","journal-title":"Am. J. Pathol"},{"key":"2022082522372331700_CIT0112","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.molmed.2015.01.005","article-title":"Molecular and immunological biomarkers to predict IVIg response","volume":"21","author":"Galeotti","year":"2015","journal-title":"Trends Mol. Med"},{"key":"2022082522372331700_CIT0113","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.tips.2015.04.012","article-title":"IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties","volume":"36","author":"Bayry","year":"2015","journal-title":"Trends Pharmacol. Sci"}],"container-title":["International Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/intimm\/article-pdf\/29\/11\/491\/45537788\/intimm_29_11_491.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/intimm\/article-pdf\/29\/11\/491\/45537788\/intimm_29_11_491.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:46:55Z","timestamp":1719276415000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/intimm\/article\/29\/11\/491\/3897037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,20]]},"references-count":113,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,7,20]]},"published-print":{"date-parts":[[2017,12,30]]}},"URL":"https:\/\/doi.org\/10.1093\/intimm\/dxx039","relation":{},"ISSN":["0953-8178","1460-2377"],"issn-type":[{"value":"0953-8178","type":"print"},{"value":"1460-2377","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11]]},"published":{"date-parts":[[2017,7,20]]}}}